Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanostart AG: Successful exit in the US

Abstract:
* Nanostart holding BioMicro sells remaining assets to US diagnostics company
* 3.2 million US dollars in revenue generated
* Remaining assets sold following Roche transaction
* "BioMicro has achieved its objective"

Nanostart AG: Successful exit in the US

Frankfurt am Main/ Salt Lake City | Posted on December 1st, 2010

Nanostart (OTCQX: NASRY) holding BioMicro has sold its remaining assets for a profit to US diagnostics company IRIS (Nasdaq: IRIS) for 3.2 million US dollars. The asset sold is an analysis product line that automatically performs high-performance tests on the genetic material of somatic cells.

With this transaction, the remaining assets of BioMicro have now been successfully sold. In March of this past year, BioMicro sold its main product - the entire MAUI system line - to global leader Roche within the framework of an asset deal. A portion of revenues from the transaction will be entered as net income on the 2010 annual financial statement. The remaining portion will be applied to the first half of 2011.

With an 8.4 percent holding in BioMicro, Nanostart will receive a corresponding disbursement from the transaction. Upon completion of the upcoming payments, the exit of BioMicro from the Nanostart portfolio will have reached a successful conclusion.

Nanostart CEO Marco Beckmann observes: "The shareholding in this highly innovative company has paid off for us. The transaction marks yet another successful exit and confirms our position as the world's leading nanotechnology investor. With the sale of BioMicro assets to a life science company, Nanostart has achieved its objective."

IRIS International, Inc. (Nasdaq: IRIS) is a leading producer of automated laboratory diagnostic systems and provider of high-quality products and tests for personalized medicine, in which individualized medications are developed based on genetic testing. The product line, which has now been sold, allows a special process - "fluorescent in-situ hybridization" - to be conducted. This new acquisition complements the IRIS product palette. Similar devices with less functionality achieve market prices between 35,000 and 60,000 US dollars according to company figures.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia, or Japan.

####

About Nanostart AG
Nanostart AG (OTCQX:NASRY), headquartered in the German financial capital of Frankfurt, is the world’s leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences, and IT/electronics. Through its subsidiary and venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government.

For more information, please click here

Contacts:
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestraße 26-28
60313 Frankfurt am Main, Germany
Tel: +49 69-21 93 96 111
Fax: +49 69-21 93 96 122

Copyright © Nanostart AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Nanomedicine

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

Announcements

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Financial Reports

Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014

Acid folic was used in the production of the nanogel as targeting agent in drug delivery. The nanogel can be used in the treatment of cancer as a stable nanocarrier. Stability of nanocarriers is an important issue in target delivery mechanisms. Most of nanocarriers, due to their March 17th, 2014

Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014

Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014

Acquisitions/Mergers/Splits

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

Applied Nanotech Holdings, Inc. (OTCQB: APNT) and Nanofilm, Ltd. Sign Merger Agreement March 14th, 2014

Harris & Harris Group Notes Molecular Imprints' Semiconductor Business To Be Acquired By Canon February 14th, 2014

FEI Buys Digital Rock Solutions Provider and microCT Product: Lithicon’s Solutions Will Expand FEI’s Oil & Gas Industry Offerings February 5th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE